Fig. 2.

Cytotoxic activity of BrHPP and zoledronate expanded Vγ9Vδ2 T cells against tumor cells. PBMCs from three donors were treated at day 0 with 300 nM BrHPP or 1 μM zoledronate and cultured in presence of 400 IU IL-2/ml within 2 weeks. Expanded cells were incubated for 4 h with 5 × 10³ target cells previously labeled with ⁵¹Cr in ratio effector to target (E/T) of 50/1 and 10/1. Target cells were HepG2 (n = 9) and HuH7 (n = 6) HCC cell lines and C181 (n = 3) CRC cell line